Results 1 to 10 of about 253,625 (250)

Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Oncol Ther
Mehr S, Hauke R.
europepmc   +1 more source

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases. [PDF]

Future Oncol
Tombal B, Saad F, Gallardo E, Soares A, Loriot Y, McDermott R, Briers E, Lagström M, Coens C, Poncet C, Fournier B, Gillessen S.   +11 more
europepmc   +1 more source

Immune Modulation During Treatment with Enzalutamide Alone or with Radium-223 in Patients with Castration Resistant Prostate Cancer. [PDF]

Cancers (Basel)
Zang PD, Da Silva DM, Liu ZX, Kandukuri S, Tsao-Wei D, D'Souza A, Kast WM, Pal SK, Kefauver C, Juanqueira M, Yang L, Quinn DI, Dorff TB.   +12 more
europepmc   +1 more source

Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models. [PDF]

Int J Mol Sci
Hagemann UB, Schatz CA, Suominen MI, Schlicker A, Knuuttila M, Wilson T, Alhoniemi E, Käkönen SM, Haendler B, Scholz A.   +9 more
europepmc   +1 more source

Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 Treatment. [PDF]

Cancer Diagn Progn
Nishimoto M, Fujita K, Ri A, Fujimoto S, Oguma Y, Toyoda S, Hashimoto M, Kikuchi T, Adomi S, Saito Y, Mori Y, Minami T, Nozawa M, Yoshimura K, Hosono M, Uemura H.   +15 more
europepmc   +1 more source

Treatment outcomes with radium-223 in patients with metastatic castration-resistant prostate cancer with bone metastasis in real-world practice: a multiinstitutional study. [PDF]

Prostate Int
Kitano H, Hashimoto K, Hasegawa Y, Fujita A, Shinmei S, Kirishima F, Shirane S, Asami A, Naito M, Kohada Y, Kobatake K, Sekino Y, Kato M, Kadonishi Y, Mochizuki H, Kajiwara M, Hinata N.   +16 more
europepmc   +1 more source

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. [PDF]

Front Med (Lausanne)
Shore N, Carles J, McDermott R, Agarwal N, Tombal B.   +4 more
europepmc   +1 more source

Racial Differences in Radium-223 Treatment Response and Adverse Effects in a Small-Cohort, Pilot, Hypothesis-Generating Observational Study. [PDF]

Ochsner J
Yang J, Nittala MR, Vijayakumar S, Vijayakumar V.   +3 more
europepmc   +1 more source

Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis. [PDF]

Transl Cancer Res
Monzen S, Kasai Y, Kinbara R, Suto K, Morino Y, Terada K, Wojcik A, Mariya Y.   +7 more
europepmc   +1 more source